Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Cornell Pochily Investment Advisors Inc.

Cornell Pochily Investment Advisors Inc. lessened its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,980 shares of the medical equipment provider’s stock after selling 918 shares during the period. Cornell Pochily Investment Advisors Inc.’s holdings in Zimmer Biomet were worth $850,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Fairfield Bush & CO. purchased a new stake in Zimmer Biomet during the first quarter valued at about $111,000. United Bank lifted its position in shares of Zimmer Biomet by 4.1% in the first quarter. United Bank now owns 11,072 shares of the medical equipment provider’s stock worth $1,416,000 after purchasing an additional 437 shares in the last quarter. Panagora Asset Management Inc. lifted its position in shares of Zimmer Biomet by 153.9% in the first quarter. Panagora Asset Management Inc. now owns 9,803 shares of the medical equipment provider’s stock worth $1,254,000 after purchasing an additional 5,942 shares in the last quarter. Aviva PLC lifted its position in shares of Zimmer Biomet by 0.4% in the first quarter. Aviva PLC now owns 30,636 shares of the medical equipment provider’s stock worth $3,918,000 after purchasing an additional 137 shares in the last quarter. Finally, Allianz Asset Management GmbH lifted its position in shares of Zimmer Biomet by 11.2% in the first quarter. Allianz Asset Management GmbH now owns 41,816 shares of the medical equipment provider’s stock worth $5,348,000 after purchasing an additional 4,224 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

ZBH traded up $0.03 during trading on Thursday, reaching $132.64. 419,545 shares of the company were exchanged, compared to its average volume of 1,545,005. The company’s 50-day moving average is $125.25 and its two-hundred day moving average is $118.03. The company has a market cap of $27.20 billion, a price-to-earnings ratio of 27.12, a P/E/G ratio of 2.35 and a beta of 1.01. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $149.25.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.88 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a dividend of $0.24 per share. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.72%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Truist Financial raised their price objective on shares of Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a research report on Friday, February 9th. TheStreet upgraded shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Morgan Stanley raised their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday, December 4th. StockNews.com downgraded shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 19th. Finally, Barclays raised their price objective on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research note on Monday, February 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $137.84.

Insider Activity

In other news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.95% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.